Clinical Trials Logo

Clinical Trial Summary

Is to investigate retinal microvascular changes in primary open angle glaucoma patients using Optical Coherence Tomography Angiography.


Clinical Trial Description

Optical coherence tomography angiography (OCT-A) is a non-invasive imaging technique developed to visualize vascular networks in the retina and choroid. It utilizes low-coherence interferometry to measure changes in backscattered signal to differentiate areas of blood flow from areas of static tissue. OCTA provides both structural and functional (i.e. blood flow) information in tandem. The "corresponding" OCT b-scans can be co-registered with the simultaneous OCT angiograms so the operator is able to scroll through the OCT angiogram like a cube scan. As a result, the precise location of pathology can be viewed on the corresponding OCT b-scans. This makes OCTA a better tool when detecting the exact location of a retinal pathology. Glaucoma is the first cause of irreversible blindness and represents approximately 15% of all causes of blindness . This makes it a real public health problem. In 2020, glaucoma affected about 80 million people worldwide, with nearly 75% of open-angle glaucoma Primary open-angle glaucoma (POAG) is a chronic, progressive, blinding, irreversible optic neuropathy characterized by damage to the optic nerve head and retinal nerve fibers with subsequent visual field defects ,elevated intraocular pressure (IOP) is a crucial glaucoma risk factor that causes direct damage to RGCs and the optic nerve . Moreover, glaucomatous retinsl ganglion cells loss occurs as well in people with normal IOP, implying mechanisms behind pressure-mediated damage. RGCs death may be due to the reduced blood supply and microvasculature dysfunction may be essential in glaucoma pathogenesis . One hypothesis is that POAG is categorized by impaired chemical endothelial signaling between both: a) the inner wall Schlemm's canal endothelial cells as well as endothelial cells located in the ciliary body and the posterior longitudinal muscle that helps to set outflow resistance and b) the ocular vascular endothelial cell and underlying luminal smooth muscle for vessels supplying the retinal ganglion cells (RGCs). This hypothesis could explain why POAG occurs across a spectrum of IOP but it does not consider the role systemic endothelial cell dysfunction may play in the disease. The non-invasive technique of OCT angiography (OCTA) can image and quantify both large vessels and the microvasculature of the optic nerve head (ONH), retina and choroid layers . Using the OCTA technique, reduced vessel density (VD) was observed in the ONH, peripapillary area and macula, predominantly in primary open-angle glaucoma (POAG) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06214676
Study type Observational
Source Assiut University
Contact Yara Ahmed
Phone 01062165361
Email ayara1942@gmail.com
Status Not yet recruiting
Phase
Start date April 2024
Completion date February 2025

See also
  Status Clinical Trial Phase
Completed NCT03284853 - Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension Phase 3
Terminated NCT03611530 - CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma N/A
Not yet recruiting NCT06441643 - Next Generation Rocklatan Phase 2
Not yet recruiting NCT02868502 - Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma N/A
Completed NCT02272569 - STARflo European Safety and Efficacy Study N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT01936389 - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma Phase 2
Completed NCT00941525 - Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure Phase 4
Completed NCT00539526 - Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Phase 4
Completed NCT00121147 - Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan N/A
Active, not recruiting NCT05035394 - Swedish Microinvasive Glaucoma Surgery Study (SMIGS) N/A
Completed NCT03450629 - Evaluation of Safety and Efficacy of PDP-716 Phase 3
Active, not recruiting NCT06061718 - Travoprost Intraocular Implant in Conjunction With Cataract Surgery Phase 3
Recruiting NCT05241938 - PSLT Compared to Prostaglandin Analogue Eye Drops N/A
Completed NCT01342406 - Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics
Completed NCT02250612 - SYL040012, Treatment for Open Angle Glaucoma Phase 2
Completed NCT01937299 - Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Phase 4
Terminated NCT01983579 - TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Phase 4
Completed NCT01937312 - Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Phase 4
Completed NCT01229982 - A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma Phase 2